JOURNAL OF RHEUMATOLOGY, published by the J Rheumatol Publ Co, stands as a distinguished platform within the fields of rheumatology and immunology since its inception in 1974. With an impressive impact evidenced by its 2023 rankings—Q1 in Rheumatology and Q2 in both Immunology and Allergy—the journal has secured its position as a vital resource for researchers and practitioners alike. The journal is dedicated to advancing clinical and experimental knowledge in the pathogenesis, diagnosis, and management of rheumatic diseases, providing a rich repository of peer-reviewed articles that drive innovation in treatment protocols and patient care. Although it operates under a subscription model, the journal remains accessible to a broad audience committed to advancing their understanding of these critical areas. Located in Toronto, Canada, it continues to attract contributions from leading experts globally, making it an essential read for anyone keen on staying at the forefront of rheumatological research and practice.

ANNALS OF THE RHEUMATIC DISEASES, published by BMJ Publishing Group, stands as a leading academic journal in the realm of rheumatology and related fields, including biochemistry, immunology, and genetics. With an esteemed impact factor and a consistent ranking in the upper echelons of its category (Q1) as per the latest evaluations, this journal represents the forefront of research and innovation, fostering scientific advancement from 1945 to the present. As the top journal in the Medicine - Rheumatology category and achieving remarkable percentiles in various interdisciplinary categories, it serves as a critical platform for researchers, clinicians, and students dedicated to understanding and addressing rheumatic diseases. Although it does not currently offer open access, its rigorous peer-review process ensures the dissemination of high-quality research findings that are paramount in enhancing clinical practices and advancing scientific discourse. Readers can expect to be challenged and inspired by the breadth of studies and reviews that address the complexities of rheumatology and its intersecting scientific domains.

European Journal of Rheumatology is a premier, peer-reviewed journal that has been paving the way for innovative research and in-depth analysis in the field of rheumatology since its launch. Published by AVES, this Open Access journal has been accessible to researchers, professionals, and students worldwide since 2014, promoting the sharing of valuable knowledge on rheumatic diseases and their treatment. With an ISSN of 2147-9720 and an E-ISSN of 2148-4279, it provides a prominent platform for groundbreaking studies and clinical evaluations that bridge scientific discovery with practical application. The journal’s mission is to enhance the understanding of rheumatological conditions and facilitate advancements in therapeutic strategies, making it an essential resource for anyone devoted to the improvement of patient care in this dynamic field. The European Journal of Rheumatology is committed to upholding the highest standards of scholarly publishing and aims to foster collaboration among researchers and practitioners across Europe and beyond.

Open Access Rheumatology-Research and Reviews, published by DOVE MEDICAL PRESS LTD, is a distinguished journal that has been a vital part of the rheumatology field since its inception in 2009. With an ISSN of 1179-156X, this journal is dedicated to disseminating groundbreaking research and comprehensive reviews in the discipline of rheumatology, making it an essential resource for researchers, clinicians, and students alike. It boasts an impressive Q3 ranking in the Rheumatology category for 2023, reflecting its relevance and quality within a highly competitive landscape, where it ranks in the 51st percentile among its peers as indicated by the Scopus Ranks. As an open-access platform, it ensures that critical findings and insights are easily accessible to a global audience, promoting collaboration and knowledge sharing. The journal's scope includes a wide range of topics within rheumatology, aimed at advancing understanding and treatment of musculoskeletal disorders and autoimmune diseases. Its headquarters is located in New Zealand, positioning it as a key player in the international research community.

Rheumatic Disease Clinics of North America is a premier journal published by W B Saunders Co-Elsevier Inc, dedicated to advancing the field of rheumatology through comprehensive and impactful research. With an ISSN of 0889-857X and an E-ISSN of 1558-3163, this esteemed publication has been disseminating knowledge since its inception in 1987, and continues to guide clinicians and researchers alike through its insightful articles and case studies. Positioned in the 2023 Q2 quartile for Rheumatology, it ranks #31 out of 73 journals in the Scopus category of Medicine _ Rheumatology, reflecting a commendable impact factor and relevance in the academic community. Although it does not offer open access options, the journal ensures that subscribers have access to cutting-edge research and reviews that address contemporary challenges and advancements in rheumatic disease. With its authoritative content, Rheumatic Disease Clinics of North America serves as a vital resource for those striving to improve patient care and clinical outcomes in the ever-evolving landscape of rheumatology research.

Reumatismo is a distinguished Open Access journal dedicated to the field of rheumatology, published by PAGEPRESS PUBL since 2001. With a rich history dating back to 1952, this journal has been pivotal in disseminating vital research on rheumatic diseases and related disorders. Based in Italy, Reumatismo has earned a reputation for its quality and relevance, achieving a Q3 category ranking in the 2023 Scopus metrics for Rheumatology, reflecting its significant contributions to the field. The journal is committed to providing a platform for the latest scientific developments and clinical innovations, thus aiding researchers, healthcare professionals, and students striving to enhance understanding and treatment of rheumatic conditions. For those seeking to access comprehensive research articles and studies, Reumatismo boasts an open access policy, ensuring that knowledge is freely available to all, fostering collaboration and advancement in rheumatology worldwide.

Journal of Rheumatic Diseases, published by the Korean College of Rheumatology, stands as a pivotal platform in the field of rheumatology, contributing significantly to the advancement of knowledge and clinical practice since its inception. With an impact factor reflecting its esteemed position in the academic community, this open-access journal promotes accessibility to high-quality research, ensuring that groundbreaking discoveries are reachable to all stakeholders in the realm of rheumatic diseases. The journal has maintained its commitment to quality, evidenced by its ranking in the Q3 category for Rheumatology in 2023, and its presence among the top quartiles of medical research. Focusing on innovative therapeutic approaches, emerging diagnostic techniques, and comprehensive reviews, the Journal of Rheumatic Diseases seeks to foster collaboration and dialogue among researchers, clinicians, and students alike. For accessibility, the journal offers numerous articles since its transition to open access in 2017, thereby facilitating research dissemination across the globe. As it converges over the years from 2019 to 2024, the journal promises to be instrumental in shaping the future of rheumatic disease research, inviting contributions that inspire new frontiers in this essential field.

SEMINARS IN ARTHRITIS AND RHEUMATISM, published by W B Saunders Co-Elsevier Inc, is a leading journal in the fields of rheumatology and pain medicine. With an impressive impact factor and recognized as a Q1 journal in both its categories, it ranks #8 in Anesthesiology and Pain Medicine and #11 in Rheumatology based on the latest Scopus data, placing it within the top echelons of academic research. Established in 1971, this esteemed publication offers a comprehensive platform for researchers and practitioners to disseminate and engage with cutting-edge studies that advance the understanding and treatment of arthritis and related conditions. With its robust editorial process and focus on high-quality, peer-reviewed articles, the journal not only contributes to scientific knowledge but also serves as an essential resource for professionals and students seeking contemporary insights into effective management strategies and emerging therapies in the rheumatologic field. Although it does not offer open access, its subscription model ensures a wide distribution among academic and clinical institutions, reinforcing its significance in the research community.

BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, published by Elsevier, stands as a premier journal in the field of rheumatology, holding a prestigious Q1 ranking in both Medicine (miscellaneous) and Rheumatology categories as of 2023. With an ISSN of 1521-6942 and an E-ISSN of 1521-1770, the journal is dedicated to advancing clinical knowledge and practice through the dissemination of high-quality, peer-reviewed research. Since its inception in 1995, this journal has provided a platform for researchers, clinicians, and healthcare providers to share significant advancements, best practices, and innovative insights that shape the standards of care in rheumatology. The commitment to open access publishing reflects its mission to broaden the reach of critical research findings, ensuring that professionals across the globe can access valuable information in this vital field. The journal's impressive Scopus ranking, positioned at #10 out of 73 in Medicine-Rheumatology, alongside its notable impact factor, underscores its importance and influence in guiding clinical practice and policy in rheumatologic conditions. By engaging with this journal, readers can stay informed about emerging trends and evidence-based strategies that are crucial for improving patient outcomes.

BMC Rheumatology is a vital open-access journal that has been disseminating high-quality research in the field of rheumatology since its inception in 2017. Published by Springer Nature, this journal provides a platform for original research, reviews, and clinical studies that advance the understanding and treatment of rheumatic diseases. With a commendable impact factor and ranked in the second quartile (Q2) for Rheumatology as of 2023, BMC Rheumatology exemplifies expertise, contributing significantly to the medical community's dialogue. Researchers, professionals, and students will find valuable insights within its pages, as it caters to a diverse audience through its commitment to open-access publishing, facilitating knowledge sharing without barriers. Based in the United Kingdom and indexed in Scopus, the journal continues to thrive with a steady convergence of academic excellence through 2024, making it an indispensable resource for those dedicated to advancing rheumatological science.